Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has decided not to lower the conversion price of its convertible bonds, Huahai Convertible Bonds, despite the stock price falling below the threshold for adjustment [1][4][14]. Group 1: Board Meeting and Decisions - The third temporary meeting of the ninth board of directors was held on August 15, 2025, with all nine directors present, meeting the legal requirements for the meeting [1]. - The board unanimously approved the proposal not to lower the conversion price of the Huahai Convertible Bonds [1][4]. Group 2: Convertible Bond Details - As of August 15, 2025, the company's stock price had been below 80% of the current conversion price for at least 15 trading days within any 30 consecutive trading days, triggering the adjustment clause [4][13]. - The initial conversion price was set at 34.66 CNY per share, with the latest conversion price adjusted to 33.06 CNY per share [5][9]. - The company issued 18.426 million convertible bonds with a total amount of 1.8426 billion CNY, with a maturity of six years from the issuance date [5]. Group 3: Future Considerations - The board will not propose a downward adjustment for the conversion price in the next two months (from August 16 to October 15, 2025), even if the adjustment clause is triggered again [4][14]. - Starting from October 16, 2025, if the adjustment clause is triggered again, the board will convene to consider whether to exercise the right to adjust the conversion price [5][14].

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. held its third temporary meeting of the ninth board of directors on August 15, 2025, where it was decided not to lower the conversion price of the "Huahai Convertible Bonds" [1]. Group 1 - The meeting was attended by all nine directors, meeting the legal quorum requirements [1]. - The resolution regarding the non-adjustment of the conversion price for the "Huahai Convertible Bonds" was passed unanimously with 9 votes in favor and no votes against or abstentions [1]. - The details of the resolution will be published in various financial newspapers and on the Shanghai Stock Exchange website [1].

Core Viewpoint - Huahai Pharmaceutical (600521) announced that its board of directors decided not to exercise the right to lower the conversion price of "Huahai Convertible Bonds" for the current period and will not propose a downward adjustment in the next two months [1] Group 1 - The board resolution was made during the third temporary meeting of the ninth board of directors [1] - The period for potential downward adjustment of the conversion price is set from August 16, 2025, to October 15, 2025 [1] - Starting from October 16, 2025, the company will reassess whether to exercise the right to adjust the conversion price if the conditions are met [1]

Group 1 - The core point of the article is that Huahai Pharmaceutical announced the decision not to adjust the conversion price of its "Huahai Convertible Bonds" during the third temporary meeting of the ninth board of directors [2]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 | 2025-089 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于不向下修正"华海转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至 2025 年 8 月 15 日，浙江华海药业股份有限公司（以下简称"公司"） 股价已出现任意三十个连续交易日中至少十五个交易日收盘价格低于当期转股 价格 80%的情形，触及"华海转债"转股价格向下修正条款。 经公司第九届董事会第三次临时会议审议通过，公司董事会决议本次不行使 "华海转债"转股价格向下修正的权利，且在未来 2 个月内（2025 年 8 月 16 日 至 2025 年 10 月 15 日），如再次触及可转债的转股价格向下修正条款，亦不提出 向下修正方案。从 2025 年 10 月 16 日开始重新起算，若再次触发"华海转债" 转股价格向下修正 ...

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2025-088 号 浙江华海药业股份有限公司 第九届董事会第三次临时会议决议公告 一、审议通过了《关于不向下修正"华海转债"转股价格的议案》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 具体内容详见公司于 2025 年 8 月 16 日刊登在中国证券报、上海证券报、证券 时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的《浙江华海药业股 份有限公司关于不向下修正"华海转债"转股价格的公告》。 特此公告。 浙江华海药业股份有限公司 董事会 二零二五年八月十五日 1 / 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第三次临时会议于 二零二五年八月十五日下午十五点以通讯方式在公司四楼会议室召开。会议应到会 董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董事 长李宏先生主持。会议程序符合《公司法》及《公司章程》的规 ...

Core Viewpoint - The hypertension medication market in China is experiencing significant changes due to national centralized procurement, leading to a decline in overall sales and a shift in market dynamics [1][2][18]. Market Overview - The sales scale of hypertension medications in the hospital terminal market has decreased from over 60 billion yuan in 2019 to 47.726 billion yuan in 2024, reflecting a year-on-year decline of 4.16% [2][18]. - Prior to 2018, the market growth rate was consistently above 10%, peaking at 60.932 billion yuan in 2019 [2]. Drug Categories - Drugs acting on the renin-angiotensin system (RAS) hold the largest market share at 41.22%, followed by calcium channel blockers at 37.57% [4]. - Oral medications dominate the market, accounting for over 90% of sales, while intravenous injections represent 8.42% [4]. Top 10 Drugs - The top 10 hypertension medications in 2024 include: 1. Sacubitril/Valsartan 2. Nifedipine Controlled Release 3. Amlodipine Besylate 4. Metoprolol Succinate 5. Lercanidipine 6. Irbesartan/Hydrochlorothiazide 7. Valsartan/Amlodipine 8. Felodipine Controlled Release 9. Valsartan/Hydrochlorothiazide 10. Aliskiren [6][8]. Sales Performance - Among the top 10 drugs, only two achieved positive growth in 2024: Sacubitril/Valsartan with a 30.96% increase and Aliskiren with a 20.89% increase [9]. - Nifedipine Controlled Release, once the market leader, has seen its sales drop significantly, nearing a halving since the implementation of centralized procurement [10][18]. Competitive Landscape - The market is characterized by intense competition, with 27 manufacturers producing Nifedipine Controlled Release, leading to a drastic reduction in its market share [10][12]. - In 2024, foreign companies like Novartis and Bayer continue to dominate the top positions in the hypertension medication market, while six domestic companies have also made it to the top 10 [15][18]. Conclusion - The implementation of centralized procurement has reshaped the hypertension medication market, resulting in a significant decline in sales and a rise of innovative drugs like Sacubitril/Valsartan, which combines blood pressure reduction with heart protection [18].

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has established a new subsidiary, Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd., with an investment of 400 million RMB, focusing on research and experimental development in the pharmaceutical industry [1] Company Summary - Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd. was founded on September 23, 2024, with a registered capital of 400 million RMB and is wholly owned by Zhejiang Huahai Pharmaceutical Co., Ltd. [1] - The company is located in Shanghai and is involved in various activities including medical research and experimental development, import and export of goods and technology, data processing and storage support services, and various technical services [1] - The company is authorized to engage in several licensed activities such as drug production, wholesale, retail, import and export, contract manufacturing, and clinical trial services, subject to regulatory approvals [1] Industry Summary - The establishment of Huahai Tianheng indicates a strategic move within the pharmaceutical industry, emphasizing the importance of research and development in enhancing the company's capabilities and market position [1]

Core Viewpoint - The synthetic biology sector in food and agriculture has entered a period of explosive investment and development, focusing on the production of alternative proteins and other innovative food products [2]. Group 1: Investment and Development Trends - The application of synthetic biology in food nutrition is increasing annually, with a focus on products such as edible microbial proteins, functional sugars, probiotics, human milk oligosaccharides, EPA, DHA, collagen, and cultured meat [2]. - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference will be held from August 20-22 in Ningbo, Zhejiang, featuring representatives from various universities and companies sharing insights on synthetic biology technology and product development [3]. Group 2: Conference Agenda Highlights - The conference will include sessions on innovative research and industrial transformation of probiotics, bio-manufacturing of human milk oligosaccharides, and the development of vitamins and agricultural enhancers [6][19][39]. - Notable speakers include experts from Jiangnan University, Yili Group, and other leading companies in the field, discussing topics such as sweet proteins and green agricultural enhancers [6][39]. Group 3: Industry Collaboration and Support - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd., in collaboration with various academic and research institutions, highlighting the importance of industry-academia partnerships in advancing synthetic biology [9][10]. - Strategic cooperation with media and industry alliances is emphasized to promote the growth of the synthetic biology sector [10][31].

Core Viewpoint - The article discusses the approval and details of the Guangdong Province Synthetic Biology Manufacturing Pilot Platform Project, highlighting its investment, construction scale, and the upcoming SynBioCon 2025 conference focused on synthetic biology and green manufacturing trends [3][4][5]. Project Approval and Details - The Guangdong Provincial Development and Reform Commission approved the preliminary design budget for the Synthetic Biology Manufacturing Pilot Platform Project, with a total investment of 21,733,000 yuan, including engineering costs of 19,459,000 yuan and other expenses [3]. - The project will establish four major pilot platforms: an intelligent microbial pilot platform, a functional macromolecule pilot platform, a green biomass methanol pilot platform, and an intelligent plant pilot platform, covering a construction area of approximately 8,500 square meters and acquiring about 365 sets of instruments and equipment [3][4]. SynBioCon 2025 Conference - The SynBioCon 2025 conference will be held from August 20 to 22 in Ningbo, Zhejiang, focusing on four main areas: AI in biological manufacturing, green chemical engineering and new materials, future food, and future agriculture [5]. - The conference aims to explore the development trends of the biological manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the continuous vitality brought by new technologies and products [5]. - Various activities will take place during the conference, including a youth forum, high-level discussions, and a closed-door seminar on the "2025 Blue Book for AI Empowering Biological Manufacturing Industry Innovation" [5][11].